
Indian pharma, med-tech sectors should transform from cost-based to value and innovation-based industry: Mandaviya
The Hindu
Speaking about the benefits of the scheme, the Minister said it would focus on transforming India into a high-volume, high-value player in the global market of pharmaceuticals, meeting the quality, accessibility, and affordability goals.
The Indian pharmaceutical and med-tech sectors need to be transformed from a cost-based to a value and innovation-based industry, Union Minister for Chemicals and Fertilizers Mansukh Mandaviya said on September 26.
Mr. Mandaviya was speaking at the launch of the National Policy on Research and Development and Innovation in Pharma-MedTech Sector and the Scheme for Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP).
Speaking about the benefits of the scheme, the Minister said it would focus on transforming India into a high-volume, high-value player in the global market of pharmaceuticals, meeting the quality, accessibility, and affordability goals.
“The policy will help to create an ecosystem of skills and capacities including the academia and the private sectors and give impetus to new talent among the youth through start-ups,” he said.
It will also enhance India’s share in the global value chain, the Minister said.
He said India needed to do mass production of pharmaceutical products and medical devices, and for this “we have made three bulk drug parks in Himachal Pradesh, Visakhapatnam and Gujarat and four medical device parks in Himachal Pradesh, Uttar Pradesh, Madhya Pradesh and Tamil Nadu, which will help in strengthening this sector”.

The Union Home Ministry has announced a major policy shift for ex-Agniveers, raising their reservation in Group C posts of the Central Armed Police Forces from 10% to 50%, starting with the Border Security Force. Ex-Agniveers are exempt from physical tests but must clear written exams, with a minimum qualification of Class 10 pass. The move aims to provide stable government jobs for Agniveers retiring in 2026, sparking debate on its impact on other candidates.












